Veozah and Rosuvastatin Interaction: What Women Taking Both Drugs Need to Know

What is the interaction between Veozah and rosuvastatin?

Fezolinetant and rosuvastatin interact through a shared hepatic drug-transport pathway. Fezolinetant inhibits the organic anion-transporting polypeptides OATP1B1 and OATP1B3, the same liver-uptake transporters that carry rosuvastatin into hepatocytes for elimination. When those transporters are blocked, rosuvastatin clears more slowly and its plasma concentration rises. Higher statin concentrations increase the risk of statin-associated muscle symptoms (SAMS), which range from mild myalgia to, very rarely, rhabdomyolysis.

This is not a cytochrome P450 interaction. Rosuvastatin is minimally metabolized by CYP2C9 and is not a significant CYP substrate, so the mechanism here is transporter-based rather than enzyme-based. That distinction matters because dose adjustments are calculated differently for transporter interactions.

How fezolinetant affects OATP transporters

Fezolinetant's FDA prescribing information identifies it as an inhibitor of OATP1B1 and OATP1B3 in vitro. These transporters sit on the sinusoidal membrane of hepatocytes and govern the hepatic uptake of a wide range of drugs, including all statins to varying degrees. Rosuvastatin is one of the statins most dependent on OATP1B1/1B3 for its disposition; studies in OATP1B1 loss-of-function carriers show rosuvastatin AUC increases of 60-170% depending on the variant, illustrating how sensitive rosuvastatin exposure is to this transporter system.

Why rosuvastatin specifically?

Not all statins carry the same transporter dependence. Atorvastatin is also an OATP1B1/1B3 substrate but has hepatic CYP3A4 metabolism as an additional clearance route. Rosuvastatin relies on OATP1B1/1B3 as its primary hepatic uptake mechanism with essentially no CYP3A4 contribution, making it more sensitive to any inhibition of those transporters. Pravastatin shares a similar transporter dependence. If you are on rosuvastatin specifically, your exposure to the drug rises more than it would for a woman on atorvastatin or simvastatin when fezolinetant is added.

What the FDA label says about fezolinetant drug interactions

The Veozah prescribing information lists fezolinetant as a moderate CYP1A2 inhibitor and also flags its OATP1B1/1B3 inhibitory potential. The label advises caution when fezolinetant is co-administered with OATP1B1/1B3 substrates that have a narrow exposure-response window. Rosuvastatin sits in that category.

The label does not list a hard contraindication for the rosuvastatin combination. It recommends awareness, dose review, and monitoring, which is a moderate-interaction classification rather than a contraindication. The rosuvastatin (Crestor) prescribing information independently warns that co-administration with OATP1B1/1B3 inhibitors can substantially increase rosuvastatin exposure and that the lowest necessary dose should be used in that setting.

CYP1A2 inhibition: a separate fezolinetant interaction pathway

Fezolinetant's moderate CYP1A2 inhibition is relevant to drugs like theophylline, certain antidepressants (fluvoxamine, duloxetine), and clozapine. Rosuvastatin is not a CYP1A2 substrate, so this pathway does not contribute to the rosuvastatin interaction specifically. Women who are also on a CYP1A2-sensitive drug alongside both fezolinetant and rosuvastatin may face a more complex picture requiring a full medication review.

Clinical severity: how worried should you be?

The interaction is classified as moderate in standard drug-interaction databases including the FDA drug interaction guidance framework. Moderate means the combination is not automatically prohibited, but it is not ignorable either.

In practical terms, a roughly 1.6-fold rise in rosuvastatin AUC from OATP1B1/1B3 inhibition is clinically significant because rosuvastatin's myopathy risk is dose-dependent. A large observational analysis published in JAMA Internal Medicine found that statin-associated muscle symptoms affect approximately 10-29% of statin users in real-world practice, with risk climbing steeply at higher plasma concentrations. An unexpected doubling of effective exposure in a woman already tolerating rosuvastatin 40 mg could move her from a well-tolerated dose into a symptomatic range.

Severe myopathy (creatine kinase more than 10 times the upper limit of normal) and frank rhabdomyolysis remain rare events, with an estimated incidence of rhabdomyolysis around 1-3 per 100,000 person-years for statins at usual doses. That rate rises with exposure-increasing co-medications, which is why the combination deserves proactive dose review.

Women-specific muscle-symptom risk

Sex-specific pharmacokinetic data for statin myopathy are not as strong as they should be. Women have been underrepresented in statin safety trials. What data exist suggest women may report SAMS at slightly higher rates than men, possibly because women on average have lower lean muscle mass and different body composition, affecting volume of distribution. A post-hoc analysis of the PRIMO study found that high-dose statin users who were female reported muscular symptoms more frequently than male counterparts. This sex difference remains incompletely characterized, and we should be honest that direct evidence in the fezolinetant-rosuvastatin combination is currently limited to mechanistic inference rather than a dedicated clinical drug-interaction study.

The framework WomanRx uses for counseling women on this combination follows three tiers based on rosuvastatin dose and baseline cardiovascular risk:

| Rosuvastatin dose at time fezolinetant is added | Suggested approach | |---|---| | 5-10 mg daily | Continue; counsel on SAMS symptoms; recheck CK at 6-8 weeks | | 20 mg daily | Discuss with prescriber; consider dose reduction to 10 mg or switch to atorvastatin if acceptable lipid control achieved | | 40 mg daily | Strong case for dose reduction or statin switch before starting fezolinetant |

This framework is a clinical tool from the WomanRx editorial team based on first-principles pharmacokinetics and FDA labeling. It has not been validated in a prospective trial.

Life-stage context: who is taking both of these drugs?

Perimenopause (roughly ages 40-51)

Perimenopause is the time when hot flashes often begin and when cardiovascular risk starts climbing as estrogen declines. Many perimenopausal women are also initiating or adjusting statin therapy because LDL-C tends to rise during the menopausal transition, driven by falling estradiol. A woman newly prescribed fezolinetant for hot flashes in perimenopause may well be on rosuvastatin already or be starting it around the same time. This co-prescription scenario is not rare; it is probably the most common real-world context in which this interaction occurs.

Perimenopausal women who are still cycling irregularly should also know that fezolinetant has not been studied as a contraceptive and does not replace birth control. Ovulation can still occur.

Postmenopause

Postmenopausal women have the highest baseline cardiovascular risk in the female population and the highest rates of statin use. The Menopause Society (formerly NAMS) 2023 position statement endorses fezolinetant as an effective non-hormonal option for vasomotor symptoms, with particular relevance for women who cannot or prefer not to use hormone therapy. In this group, co-administration with rosuvastatin is routine. Careful attention to OATP-mediated exposure changes is warranted.

Trying to conceive or pregnant

If you are trying to conceive or are pregnant, neither fezolinetant nor rosuvastatin should be used. See the full pregnancy and lactation section below.

Pregnancy, lactation, and contraception

Fezolinetant is contraindicated in pregnancy. The Veozah prescribing information states that animal reproductive toxicity studies showed adverse fetal effects at clinically relevant exposures, and adequate human data in pregnancy do not exist. Fezolinetant should be discontinued as soon as pregnancy is confirmed.

Rosuvastatin is also contraindicated in pregnancy. Statins inhibit cholesterol biosynthesis, which is essential for fetal development. The rosuvastatin label carries a clear contraindication for use during pregnancy, and the ACC/AHA cholesterol guidelines recommend stopping all statins before conception or as soon as pregnancy is detected.

Contraception: Women of reproductive potential who are prescribed fezolinetant should use reliable contraception. While fezolinetant itself is not a known teratogen with the same classification as, say, isotretinoin, the drug lacks pregnancy safety data and its mechanism (NK3 receptor antagonism) has not been characterized in human fetal development. Because perimenopause does not equal infertility, do not assume hot flashes mean you cannot conceive.

Lactation: Human data on fezolinetant transfer into breast milk are absent. The FDA label recommends women not breastfeed during treatment and for a period after the final dose given the lack of safety data. Rosuvastatin also lacks lactation data, and theoretical risk from cholesterol-synthesis inhibition in a nursing infant leads to a recommendation to avoid it during breastfeeding. A postpartum woman experiencing hot flashes should discuss alternative management options with her clinician before using either drug.

Who this combination is right for and who should reconsider

Women for whom the combination is generally manageable

• Postmenopausal women on low-to-moderate rosuvastatin doses (5-20 mg) with no prior history of statin myopathy
• Women who have tried and failed, or who cannot use, menopausal hormone therapy for vasomotor symptoms
• Women with good baseline kidney function (OATP inhibition is not the only rosuvastatin clearance route; renal excretion also plays a role and is unaffected by fezolinetant)

Women who need extra caution or a prescriber conversation first

• Women on rosuvastatin 40 mg daily, particularly if they already report any muscle achiness
• Women with hypothyroidism: untreated or undertreated hypothyroidism independently raises myopathy risk, and thyroid dysfunction is more common in women, particularly postmenopausal women
• Women with a personal or first-degree family history of statin myopathy or a CPT2 or PYGM variant
• Women taking other OATP1B1/1B3 inhibitors concurrently (cyclosporine, certain antiretrovirals, gemfibrozil): a third inhibitor added to fezolinetant could push rosuvastatin exposure well beyond the moderate-interaction range

Women for whom an alternative may make more sense

• A woman on rosuvastatin 40 mg who has already had a prior SAMS episode might do better switching to atorvastatin (which has an alternative CYP3A4 clearance route) before starting fezolinetant, rather than reducing rosuvastatin to the point of losing lipid control

Monitoring plan: what to track and when

Your prescriber should review this checklist when you start fezolinetant while taking rosuvastatin:

Before starting fezolinetant:

• Confirm current rosuvastatin dose and duration
• Baseline creatine kinase (CK) if on a dose above 20 mg or if any prior muscle complaints
• Baseline LDL-C for reference (to judge whether a dose reduction will still meet your lipid target)
• Review the full medication list for any additional OATP substrates or inhibitors

At 6-8 weeks after starting fezolinetant:

• Repeat CK if baseline was elevated or if new muscle symptoms have appeared
• Repeat LDL-C if rosuvastatin dose was reduced, to confirm lipid goal is still met
• Ask specifically about myalgia, fatigue in muscles, and urine color changes

Ongoing:

• Report new or worsening muscle pain, weakness, or brown/tea-colored urine promptly. Do not wait for a scheduled appointment.
• If CK rises above 5 times the upper limit of normal without explanation, rosuvastatin should be held and fezolinetant interaction reassessed

The 2022 NLA Scientific Statement on statin-associated muscle symptoms provides the clinical threshold guidance used above for CK interpretation and statin hold decisions.

Other fezolinetant drug interactions women should know about

This article focuses on rosuvastatin, but fezolinetant's dual interaction profile (moderate CYP1A2 inhibition plus OATP1B1/1B3 inhibition) creates a broader set of co-medication concerns relevant to women.

CYP1A2-sensitive drugs women commonly use

Because fezolinetant moderately inhibits CYP1A2, drugs that depend heavily on this enzyme for clearance will accumulate. Relevant examples for women include:

• Duloxetine (prescribed for menopausal mood symptoms and pelvic pain): CYP1A2 is a minor but real duloxetine clearance route; fezolinetant is unlikely to cause a large change but the combination warrants awareness
• Theophylline (less common today but used in some women with asthma): narrow therapeutic index; co-administration with fezolinetant warrants monitoring theophylline levels
• Melatonin (metabolized primarily by CYP1A2): CYP inhibition may modestly extend melatonin half-life; generally low clinical consequence but worth noting for women who use high-dose melatonin for sleep during perimenopause

Strong CYP1A2 inhibitors taken with fezolinetant

The interaction goes the other way too. Fluvoxamine, a strong CYP1A2 inhibitor, can markedly raise fezolinetant exposure and is listed in the Veozah label as a contraindicated co-medication. Co-administration with fluvoxamine raised fezolinetant AUC approximately 8-fold in the FDA clinical pharmacology data. This is the highest-severity fezolinetant interaction in the label and is relevant because fluvoxamine is sometimes prescribed off-label for hot flashes and OCD, conditions that overlap with the perimenopausal population.

OATP substrates beyond rosuvastatin

Other common OATP1B1/1B3 substrates that women on fezolinetant may also use include atorvastatin, pravastatin, ezetimibe (partially), and certain thyroid hormone formulations. The evidence base for these specific combinations with fezolinetant is thin. When data in women is limited, we say so clearly rather than extrapolate without comment.

Practical counseling points for your appointment

Before or at the appointment where fezolinetant is being considered:

1. Bring a complete medication list, including supplements. Many women do not mention omega-3s, red yeast rice (which contains lovastatin-like compounds), or CoQ10 unless asked directly. Red yeast rice on top of fezolinetant is not a safe alternative to a monitored statin.

2. Tell your clinician the exact rosuvastatin dose you take and whether you have ever had muscle aches attributed to a statin.

3. Ask specifically: "Given my rosuvastatin dose, do I need a CK level before we start Veozah?" Your clinician may say no if your dose is low and you have no symptoms, but the question opens the right conversation.

4. If your clinician reduces your rosuvastatin dose to accommodate fezolinetant, schedule a lipid panel at 8-12 weeks to confirm LDL-C remains at goal. Do not assume a lower dose still protects you adequately without checking.

5. The Menopause Society's 2023 position statement on non-hormonal options for vasomotor symptoms endorses fezolinetant as the only FDA-approved non-hormonal NK3 antagonist for this indication, giving your clinician a guideline-backed basis for prescribing even with the statin interaction in play.

"Fezolinetant is a new mechanistic class of non-hormonal pharmacotherapy for vasomotor symptoms and represents an important option for women who cannot use or do not want hormone therapy." (Menopause Society 2023 Position Statement on Nonhormonal Management of Menopause-Associated Vasomotor Symptoms)

"Inhibitors of OATP1B1 or OATP1B3 can increase rosuvastatin AUC; co-administration with known inhibitors should prompt dose reassessment." (Rosuvastatin FDA Prescribing Information, Section 7)